Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Apr 2016

Mössner Rotraut, Diering Nina, Bader Oliver, Forkel Susann, Overbeck Tobias, Gross Uwe, Grimbacher Bodo, Schön Michael P, Buhl Timo

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Candidiasis, Chronic Mucocutaneous
Share to Interleukin-17
Share to Mutation

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Nitriles

Share to Pyrazoles

Share to Pyrimidines

Share to STAT1 Transcription Factor

Share to Tongue

Source

Identifiers

PMID: 26787170
DOI: 10.1093/cid/ciw020

Genes

STAT1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation.PMID 26787170Read ↗

Stepwise Reversal of Immune Dysregulation Due to STAT1 Gain-of-Function Mutation Following Ruxolitinib Bridge Therapy and Transplantation.Semantic proximity Read ↗

A Child with Chronic Mucocutaneous Candidiasis Harbors a Novel Gain-of-Function Mutation in STAT1.Semantic proximity Read ↗

Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation.Semantic proximity Read ↗

The potential role for topical imiquimod in the treatment of chronic mucocutaneous candidiasis caused by gain-of-function mutation in STAT1: A case-report.Semantic proximity Read ↗

Novel STAT1 gain-of-function mutation and suppurative infections.Semantic proximity Read ↗

Human STAT1 gain of function with chronic mucocutaneous candidiasis: A comprehensive review for strengthening the connection between bedside observations and laboratory researchSemantic proximity Read ↗

Risks of Ruxolitinib in STAT1 Gain-of-Function-Associated Severe Fungal DiseaseSemantic proximity Read ↗

Primary immunodeficiency and chronic mucocutaneous candidiasis: pathophysiological, diagnostic, and therapeutic approaches.Semantic proximity Read ↗

Gain-of-Function Mutations inSTAT1: A Recently Defined Cause for Chronic Mucocutaneous Candidiasis Disease Mimicking Combined ImmunodeficienciesSemantic proximity Read ↗

Three adult cases of STAT1-gain-of-function with chronic mucocutaneous candidiasis treated with JAK inhibitorsSemantic proximity Read ↗

Chronic mucocutaneous candidiasis associated with an SH2 domain gain-of-function mutation that enhances STAT1 phosphorylation.Semantic proximity Read ↗

Human STAT1 Gain-of-Function Heterozygous Mutations: Chronic Mucocutaneous Candidiasis and Type I Interferonopathy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.